Fresenius Medical Care Launches UFComplete, a Collaborative Fluid-Management Program for Congestive Heart Failure Patients

  Fresenius Medical Care Launches UFComplete, a Collaborative Fluid-Management
  Program for Congestive Heart Failure Patients

Nation’s Leading Dialysis Provider Targets the Biggest Cause of U.S. Hospital

Business Wire

WALTHAM, Mass. -- October 23, 2012

Fresenius Medical Care North America (FMCNA), the nation’s leading network of
dialysis facilities, today announced the launch of UFComplete, a complete
fluid-management program for congestive heart failure (CHF) patients. The
program – which combines clinically proven ultrafiltration (UF) therapy with
cost-effective home monitoring and education initiatives – will be
administered by FMCNA’s highly trained multidisciplinary staff in
collaboration with hospitals’ own physicians and nurses.

Each year, nearly 5 million Americans are hospitalized with CHF – a condition
in which patients’ weakened hearts move blood through their bodies more slowly
than normal, causing excess fluid to build up in the arms, legs, ankles, feet,
lungs or other organs. CHF is one of the most common reasons for admission to
U.S. hospitals, often requiring lengthy and costly stays, and half of those
patients are readmitted within six months of their initial discharge.

UF therapy has been shown to slowly and safely lower patients’ excess salt and
water levels when conventional diuretic drug treatments fail. It is supported
by more than 60 years of published data and randomized clinical trials, and is
endorsed by leading heart failure experts.

FMCNA’s innovative UF therapy program builds upon its industry-leading
dialysis expertise and inpatient programs with more than 1,000 hospitals
nationwide to provide cost-effective UF treatments that significantly improve
patient outcomes, reduce hospital admissions and length of stay, and help
hospitals avoid financial penalties and the need for capital expenditures.

As part of UFComplete, after patients are discharged, they continue to receive
three months of follow-up services including daily electronic weight reporting
and 24-hour nurse phone support. Clinicians receive live alerts of patient
non-compliance or heart failure symptoms, giving them the opportunity to
intervene and treat patients earlier. FMCNA also works with hospital staff on
educational programs encouraging patients to avoid salt, exercise regularly
and take their medications daily.

“We understand that treating heart failure can be both challenging and costly,
which is why we created the UFComplete program to help reduce hospital
readmissions and length of stay,” said Dr. John Wigneswaran, Vice President of
Market Development and head of FMCNA’s UFComplete fluid-management program.
“With the added benefits of our new UFComplete program, Fresenius Medical Care
looks forward to making a real difference in treating a disease that affects
millions of Americans and creates an enormous burden on our healthcare

The UFComplete program offers an à la carte menu that can be tailored to fit
the needs of each hospital through a customized service contract, which may
include UF devices, filters and ancillary materials; skilled nurses for device
setup, take down and flowchart review and home monitoring services; and
physician oversight and management. FMCNA also is partnering with the American
Association of Heart Failure Nurses and the Cardiometabolic Health Congress to
raise CHF patients’ awareness of recommended lifestyle modifications.

For more information about this program, call toll-free at 855-362-4383 or

About Fresenius Medical Care

Fresenius Medical Care (NYSE: FMS) is the world’s leading company devoted to
patient-centered renal therapy. Through more than 3,119 clinics in North
America, Europe, Latin America, Asia-Pacific and Africa, we provide kidney
dialysis treatments to approximately 253,000 patients worldwide. We are also
the world’s leading maker of dialysis products, such as dialysis machines,
dialyzers and related disposable products. Chronic kidney failure is a
condition that affects more than 2.1 million individuals worldwide. For more
information about the company’s more than 2,100 U.S. dialysis facilities,
visit (in English and Spanish). For more
information about Fresenius Medical Care, visit or


Media contact:
Loomis Group
Jaclyn Petros, 617-638-0022 / voice
Company contact:
Fresenius Medical Care
Rosemary Heinold, 781-699-4171 / voice
Press spacebar to pause and continue. Press esc to stop.